reflects relative specificity for the meta-phenolate pyridinium structure with a 5-hydroxymethyl function. Taking advantage of this specificity, binding proteins for B6 have been isolated from renal brush border plasma membranes subjected to affinity chromatography on 4'-nvridoxamino affinoses [51.
INTRODUCTION
The uptake of vitamin B6 by mammalian cells is facilitatedat physiologic concentration. In common with the importing of water-soluble vitamins by other epithelial cells [1] , the uptake of B6 by renal proximal tubular cells [2] or vesicles from the brush border plasma membrane of such cells [3] is dependent upon Na+ cotransport. This does not appear to be the case for the nonepithelial parenchymal hepatocyte [4] . The uptake of B6 by cells from both kidney [2] and liver [4] reflects relative specificity for the meta-phenolate pyridinium structure with a 5-hydroxymethyl function. Taking advantage of this specificity, binding proteins for B6 have been isolated from renal brush border plasma membranes subjected to affinity chromatography on 4'-nvridoxamino affinoses [51.
Since the B6 transporter can accept analogues differing at position 4, it became clear one might compete with entry of the vitamin or even gain facilitated entry of N-(4'-pyridoxyl)amines which are derivatives of pyridoxamine. If the latter occurred, it would seem likely that pyridoxal kinase could catalyze phosphorylation of such analogues, because the kinase accepts all three natural vitaminic forms of B6 and several other 4f-substituted analogues [6] [7] [8] . The resulting N-(5'-phospho-4f-pyridoxypamines would be good substrates for the pyridoxamine (pyridoxine) 5f-phosphate oxidase which can act upon diverse 4'-secondary amines of B6 phosphate [9] [10] [11] [12] . Hence, if 4'-(N)-substituted pyridoxamines gained facilitated entry into cells with cytosolic kinase and oxidase activities, the end result would be formation of pyridoxal 5-phosphate with release of the original amine that had been covalently attached to B6. That this is the case has recently been demonstrated for proximal tubular cells from rat kidney [13] , and will be shown herein for both bipolar kidney and liver cells. As will be discussed, this provides one of several means to deliver cellular effectors by transporter-enhanced delivery followed by enzymecatalyzed release.
II. COMPETITION FOR B6 UPTAKE IN KIDNEY CELLS
The uptake of radiolabeled pyridoxine by isolated proximal tubular cells from rat kidney is competitively inhibited by unlabeled 4'(N)-substituted pyridoxamines, as shown in Fig. 1 . As the free amines used to make the derivatives (via borohydride reductionof aldimine intermediates from pyridoxal) had little or no significant effect on such uptake, it is likely the same transport system is involved.
III. UPTAKE OF ANALOGUES IN LIVER A 11 HONEY CELLS
The ability of the kidney cells to directly import the ifi-labeled 4:(N)-substituted pyridoxamines (made using boro[3H]hydride) was demonstrated recently [13] . The similar facilitated entry of these derivatives has now been found with isolated hepatocytes from rat liver. The kinetic parameters for these cases compared with pyridoxine are given in Table 1 . b Velocities are expressed as pmol/106 cells.min .
The initial velocities for uptake for the analogues are somewhat less than for the vitamin, but Vmax values are at least as great with activities higher in liver than kidney, possibly reflecting higher metabolic activity of the fo er. The Kt values for the analogues correspond well with their abilities to compete with pyridoxine for initial uptake.
IV. METABOLIC
EASE OF A it S The release of amines used to synthesize 4'(N)-substituted pyridoxamine 5-phosphates had been directly shown with previous examples of 14C-amino acid [9] and fluorescent conjugates [11] tested as substrates with pyridoxamine (pyridoxine) 5I-phosphate oxidase in vitro. In these and other cases [10, 13] , the concommitant liberation of pyridoxal 5-phosphate was also demonstrated. Since the oxidase only accepts the 5I-phosphates of B6 vitamers or analogues, kinase-catalyzed phosphorylation of the 4(N)-substituted pyridoxamines must occur first upon entry to cells. That this is the case was established by column chromatographic resolution of [3H]pyridoxal phosphate from products extracted from the renal cells incubated with the pyridox . ine analogues [13] .
The relative abilities of liver and kidney cells to take in and act upon 4(N)-substituted pyridoxamines to release pyridoxal phosphate (and thereby liberate the original amine) is reflected by data in Table 2. TABLE 2 Release of pyridoxal 5'-phosphate from uptake and metabolism of 4'(N)-substituted pyridoxamines by cells from liver and kidney. aMeasured as 3H-product after 50 min incubation , extraction and chromatographic purification.
The amounts of pyridoxyl phosphate determined indicate that both uptake and metabolic events generally account for the fate of the 4'(N)-substituted pyridoxamines tested in liver and kidney.
V. OVERVIEW
The use of N-(4'-pyridoxyl)amines is but one example of a system that can utilize the relative specificity of a transporter to piggyback biologically active compounds into cells that are enzymatically competent to effect their release. The enhancement of effector transport by chemical linkage to solutes that gain facilitated entry followed by cleavage to release the effector may be widely applicable and is being further developed.
